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Clarithromycin resistance in Helicobacter pylori is a principal cause of failure of eradication 
therapies, and its prevalence varies geographically. The IceA gene is a virulence factor 
associated with clinical outcomes. The objective of this study was to determine the current 
state of clarithromycin resistance prevalence, and to investigate the role of iceA genotypes 
in 87 Turkish adult patients (65 with functional dyspepsia and 22 with duodenal ulcer). 
A2143G and A2144G point mutations were tested by PCR-RFLP for clarithromycin 
resistance. Among the patients in the study, 28 patients were tested by agar dilution as 
well. Allelic variants of the iceA gene were identified by PCR. A total of 24 (27.6%) strains 
evidenced one of the mutations, either A2143G or A2144G. IceA1 was found to be positive 
in 28 of the strains (32.2%), iceA2 was positive in 12 (13.8%) and, both iceA1 and iceA2 
were positive in 22 (25.3%) strains. In conclusion, we discovered no relationships between 
iceA genotypes and functional dyspepsia or duodenal ulcer, nor between clarithromycin 
resistance and iceA genotypes. Clarithromycin resistance appears to be more prevalent in 
Turkish patients.
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The gram-negative bacterium, Helicobacter pylori (H. 
pylori), colonizes the human stomach, with prevalence 
rates from 25% in Western countries to over 90% in 
developing countries (Solerman et al., 2005). Persistent 
infection induces peptic ulcer and chronic gastritis 
(Sipponen, 1991; Graham et al., 1992) and has also 
been associated with gastric cancer and mucosal- 
associated lymphoid tissue lymphoma (Marshall, 1994; 
Bayerdorffer et al., 1995; Uemura et al., 2001). In 
1994 the IARC (World Health Organization, 1994) 
recognized H. pylori as a class 1 carcinogen.
  In 1994, the National Institutes of Health Consensus 
(NIH) recommended that all patients with peptic ulcer 
disease and documented H. pylori infection should be 
treated via appropriate antibacterial therapy (NIH, 
1994). H. pylori can be eradicated by a triple or 
quadruple therapy regimen, including the use of a 
proton-pump inhibitor (PPI) and antibiotics, primarily 
clarithromycin and amoxicillin. In Turkey, H. pylori is 
usually eradicated via a triple therapy which includes 
amoxicillin, clarithromycin, and a PPI (Guliter et al., 
2005). Following the H. pylori eradication therapy, an 
observed reduction in complications proves that H. 
pylori plays a role as an etiological agent in the 
disease. (Nomura et al., 1994). Drug resistance to H. 
pylori reduces the success rate substantially (Pounder, 
1997). The antibacterial activity of clarithromycin has 
been attributed to the inhibition of protein synthesis 
after binding to the 50S ribosomal subunit of the 
microorganism (Goldman et al., 1994). Clarithromycin 
resistance is associated with point mutations within 
the peptidyltransferase region encoded in domain V of 
the H. pylori bacterial 23S rRNA gene (Versalovic et 
al., 1996). The predominant mutations are A2143G 
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and A2144G, as well as a small number of A2143C 
mutations (Megraud et al., 1996; Alarcon et al., 
1999). Other rare mutations have also been reported, 
including G2141A, A2143T, T2183C, T2245C, 
A2144T, and T2717C (Versalovic et al., 1996; van 
Doorn et al., 1999; Ende et al., 2001; Fontana et al., 
2002; Ribeiro et al., 2003; Khan et al., 2004; 
Toracchio et al., 2004). The distribution of these 
mutations varies geographically (Dzierzanowska-Fangrat 
et al., 2001). Most people infected with H. pylori 
harbor strains that possess the cytotoxin-associated 
gene A (cagA) and vacuolating cytotoxin gene A 
(vacA) genotypes, but nonetheless remain asymptomatic. 
A novel gene was discovered by Peek et al. in 1998, 
via comparisons of mRNA transcripts from an ulcer- 
derived and a gastritis-derived H. pylori strain in 
organisms that had adhered to human gastric cells, 
versus non-adherent bacteria. The expression of this 
gene is upregulated upon the contact of the ulcer- 
derived H. pylori strain with epithelial cells, and was 
designated iceA (induced by contact with the 
epithelium). IceA also exists in allelic variants, including 
iceA1 and iceA2, and only iceA1 was induced 
following contact with the gastric epithelium. The 
IceA1 strain was associated significantly with peptic 
ulceration and increased mucosal IL-8 concentrations. 
Adherence to gastric epithelial cells in vitro stimulates 
the transcription of iceA1 (Peek et al., 1998). Some 
studies have reported an association of iceA1 strains 
with the presence of peptic ulcers, and a higher 
prevalence of iceA2 strains among patients with 
non-ulcer dyspepsia (van Doorn et al., 1998; Figueiredo 
et al., 2001). There are also some studies which have 
reported no association between iceA genotypes and 
gastric diseases (Yamaoka et al., 1999; Godoy et al., 
2003; Han et al., 2004). The prevalence of H. pylori 
clarithromycin resistance varies geographically, and 
changes in a dynamic manner (Megraud, 2004), and 
thus requires constant monitoring (Dzierzanowska- 
Fangrat et al., 2001). The primary objective of our study 
was to determine the prevalence of clarithromycin 
resistance, and to determine whether any relationship 
exists between resistance and iceA genotypes in H. 
pylori clinical isolates in Turkish patients suffering 
from duodenal ulcer or functional dyspepsia.
Materials and Methods
Patients
A total of 87 adult patients, all of whom exhibited 
symptoms of dyspepsia, were referred and followed- 
up in the Department of Gastroenterology, Ankara 
University, School of Medicine, Cebeci Hospital, were 
investigated for the presence of H. pylori between 
October 2002 and December 2003. The mean ages of 
the patients were 44±13 years, in a range from 23-72 
years of age. Among the patients, 36 were males and 
51 were females.
Culture, identification and minimal inhibitory concen-
tration (MIC) determination
Antral gastric biopsy samples were obtained from 
patients. The biopsy specimens were put into sterile 
20% dextrose solution, and transported immediately to 
the laboratory for culturing, using the standard 
method (Soltesz et al., 1992). Brain Heart Infusion 
(BHI) agar (Becton Dickinson and Company, USA) 
with 7% defibrinated horse blood, plus 5 mg/L of 
amphotericin B and 10 mg/L of vancomycin was used 
as culture media. The bacteria were cultured under 
humid conditions at 37°C in an anaerobic jar (with 
5% O2, 10% CO2, 85% N2) manufactured by 
CampyGen (Oxoid Ltd., England). The plates were 
incubated for 3-5 days. H. pylori was identified by 
morphology, Gram staining, oxidase, catalase, and 
urease tests. All isolated strains were stored at -80oC 
in brucella broth (Sigma, Germany) medium 
containing 15% (v/v) glycerol.
  The agar dilution method was applied in accord-
ance with the guidelines established by the “National 
Committee for Laboratory Standards” (NCCLS, 1999). 
Bacterial suspensions were inoculated onto Mueller- 
Hinton agar (Lab M, UK) with 5% sheep blood, 
containing clarithromycin at concentrations ranging 
from 0.032 μg/ml to 16 μg/ml. The plates were 
incubated for 72 h in a microaerobic atmosphere at 
37°C. H. pylori clarithromycin resistance was defined 
as MIC≥1 μg/ml. The H. pylori strain ATCC 43504 
was used as a quality control organism.
Genomic DNA extraction
H. pylori was cultured for 3-5 days on BHI agar 
media containing 7% defibrinated horse blood at 37°C 
in a microaerobic atmosphere. We used whole biopsy 
samples, so that all of the H. pylori DNA was 
included. The bacteria were suspended in TE buffer 
and the genomic DNA was isolated via a previously 
described method (Lee and Megraud, 1996). DNA 
was dissolved in 500 μl of sterilized distilled water 
and prepared with 0.2 μg/ml of DNA solution.
Determination of iceA
The presence of iceA was determined by a previously 
described method (Yamaoka et al., 1999). In brief, 
(detection for the iceA1 allele), iceA1F; 5’-GTGTTT 
TTAACCAAAGTATC-3’ and iceA1R; 5’-CTATAGC 
CACTCTCTTTGCA-3’ primers were used to amplify 
a 247 bp fragment. In order to detect the iceA2 allele, 
iceA2R; 5’-TTACCCTATTTTCTAGTAGGT-3’ and 
iceA2F; 5’-GTTGGGTATATCACAATTTAT 3’  primers 
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Table 1. Distribution of 23S rRNA mutations among 87 Helicobacter pylori isolated form patients with duodenal ulcer and functional 
dyspepsia in Turkey. N indicates number of isolates





A2143G 4 (18.2)*  5 (7.7)  9 (10.4)
A2144G 5 (22.7) 10 (15.4) 15 (17.2)
Total**
(A2143G+A2144G) 9 (40.9) 15 (23.1) 24 (27.6)
* Percentage of the respective disease category. ** Total of A2143G and A2144G mutations shown in different strains.
were used to amplify a 229 or 334 bp fragment. PCR 
was conducted in a 50 μl volume, containing 20 
pmol/ml of primers, 2 mM dNTP, 10× buffer (750 
mM Tris-HCl (pH 8.8 at 25°C), 200 mM (NH4)2SO4, 
0.1% Tween20, 250 mM MgCl2) (MBI Fermantas, 
Lithuania), 1 U of Taq polymerase (MBI Fermentas, 
Lithuania), and 0.2 μg/ml of H. pylori DNA. A 
thermal cycler (Eppendorf Mastercycler Personal, 
Germany) program was used for PCR, and consisted 
of 5 min of pre-denaturation at 95°C, followed by 35 
cycles of 1 min at 95°C, 1 min at 50°C for iceA1 
primers (1 min at 52°C for iceA2 primers) and 2 min 
at 72°C. A final extension step was conducted for 7 
min at 72°C. The amplified fragments were visualized 
on a 1% agarose electrophoresis gel stained with 
ethidium bromide. 
Determination of clarithromycin resistance gene
The presence of the clarithromycin resistance gene 
was determined via PCR in accordance with a pre-
viously described method (Taylor et al., 1997), followed 
by the digestion of PCR products using the BpiI and 
BsaI restriction enzymes (Sevin et al., 1998). In order 
to amplify the 310 bp fragment of the 23S rRNA gene, 
DP1; 5’-ACGGCGGCCGTAACTATA-3’ corresponding 
to positions 2357 to 2374, and ZGE23; 5’-ACAGGC 
CAGTTAGCTA-3’; complementary to positions 2649 
to 2664, primers were used (Taylor et al., 1997). 
Primers specific for H. pylori were found via a 
BLAST search of the NCBI database. PCR was 
conducted under conditions identical to that of the 
previously described iceA genotyping method, except 
with an annealing temperature of 50°C. After the 23S 
rRNA PCR, we conducted RFLP in order to detect 
23S rRNA mutations. We used the BpiI enzyme 
(Fermantas, Germany) to detect the A2143G mutation 
and BsaI (New England Biolabs, USA) to detect the 
A2144G mutation. Fifteen microliters of the amplicon 
and 5 U of the restriction enzyme with 5 μl buffer 
(10× NEBuffer3 for BsaI, Buffer G+ for BpiI) were 
incubated for 12 h at 56°C for Bsa1 and 37°C for 
BpiI. The restriction products were analyzed by 
electrophoresis on 1.5% agarose gel stained with 
ethidium bromide.
Statistical analyses
Statistical analyses were done by Chi-square and 
Fisher’s exact tests. A value of <0.05 was considered 
to be significant. If the H. pylori isolated from a 
single patient evidenced both iceA1 and iceA2 alleles 
together, the patient was considered to be harboring 
more than one strain. Therefore, these samples were 
excluded when studying the relationship between iceA 
genotypes and clinical outcome and clarithromycin 
resistance.
Results
Patient populations and bacterial isolates
Among the 87 patients in this study, 65 were 
diagnosed with functional dyspepsia (FD) and 22 with 
duodenal ulcer (DU). Standard microbiological tests 
showed that the isolates were, in fact, H. pylori, and 
those strains were subsequently verified by PCR of 
310 bp 23S rRNA gene products.
Clarithromycin resistance gene and MIC results
A total of 24 (27.6%) strains evidenced mutations, 
thereby suggesting the presence of clarithromycin 
resistance (Table 1). In patients with functional dyspep-
sia, a total of 15 strains (23.1%) evidenced mutation. 
Among them, 10 (15.4%) exhibited A2144G mutations 
and 5 (7.7%) exhibited A2143G mutations. In bacteria 
isolated from DU patients, a total of 9 (40.9 %) 
strains manifested mutations. A2144G and A2143G 
mutations were present in 5 (22.7%) and 4 (18.2%) 
isolates, respectively. No strains were found to harbor 
both the A2143G and A2144G mutations.
  Agar dilution was applied to 28 strains. Eighteen of 
them were found to harbor mutations in the 23S 
rRNA gene and 10 of them were wild-type. We 
compared the PCR-RFLP results with agar dilution 
(Table 2). All 18 of the mutant strains were determined 
to be resistant, and all 10 of the wild-type strains 
were susceptible, according to the results of the agar 
dilution studies. 
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Table 2. Comparison of 23S rRNA PCR‐RFLP results with agar 
dilution results. R: resistant to clarithromycin, S: sensitive, WT: 
wild type, N: number of isolates




Table 3. Distribution of iceA genotypes among 87 Helicobacter pylori isolated form patients with duodenal ulcer and functional dyspepsia 






iceA1 7 (31.8; 25.0)* 21 (32.3; 75.0) 28 (32.2)**
iceA2 3 (13.6; 25.0)  9 (13.8; 75.0) 12 (13.8)
iceA1+A2 3 (13.6; 13.6)   19 (29.2; 86.4) 22 (25.3)
iceA (‐) 9 (40.9; 36.0) 16 (24.6; 64.0) 25 (28.7)
*Percentages are indicated in the parenthesis. The first value is the percentage of the respective disease category, the second value 
expressing the percentage in respect to the total number of isolate for that genotype. **Percentage of the total number.
IceA genotyping
Only iceA1 was positive in 28 (FD: 21 and DU: 7) 
strains, iceA2 was positive in 12 (FD: 9 and DU: 3), 
and both iceA1 and iceA2 were positive in 22 (FD: 
19 and DU: 9) strains (Table 3). No significant 
associations were found between the iceA genotypes 
and the 23S rRNA mutations.
Discussion
Clarithromycin resistance rates vary geographically. In 
Europe, primary clarithromycin resistance rates were 
reported to occur in a range of 9.9-43.5% in two 
multi-centre studies (Glupczynski et al., 2001; van 
Doorn et al., 2001). Outside Europe, the prevalence 
of clarithromycin resistance tends to be lower 
(Megraud, 2004). In Canada, resistance was less than 
4% (Fallone, 2000). However, the prevalence of 
resistance in the USA has already reached 10-15 % 
(Laine et al., 2000; Osato et al., 2001; Laine et al., 
2003). In the Middle East, according to surveys 
conducted in Iran and Israel, the prevalence occurs in 
a range of 8-17% (Samra et al., 2002; Mohammadi et 
al., 2003). In the far East, the prevalence is higher in 
Japan (11-12%) than in Hong Kong (4.5%), Korea 
(5-6%), and New Zealand (6.8%) (Fraser et al., 1999; 
Kato et al., 2000; Teo et al., 2000; Kim et al., 2001; 
Ling et al., 2002; Perez Aldana et al., 2002; Eun et 
al., 2003; Lui et al., 2003; Megraud, 2004). In 
Turkey, resistance rates differ, but occur in a range of 
8.8-24.2 % (Sahin et al., 1994; Palabiyikoglu et al., 
1997; Inan et al., 2005; Simsek et al., 2005). 
  We observed that 27.6% (24/87) of the isolates 
were clarithromycin resistant by PCR-RFLP. Although 
it appears that resistance rates are increasing in Turkey, 
to the best of our knowledge there have been no 
reports regarding 23S rRNA mutations in H. pylori 
clinical isolates obtained from Turkish patients. In all 
of the Turkish studies, resistance was detected via 
microbiological techniques, such as disk diffusion or 
E-Test.
  Clarithromycin is an important macrolide due to its 
low MIC value, which is relatively unaffected by 
lowering the pH, as well as its high concentration in 
gastric mucosa, and the fact that it evidences the 
highest degree of interaction with regard to binding to 
H. pylori ribosomes (Goldman et al., 1994). Macrolide 
consumption is a significant problem in increasing 
clarithromycin resistance in H. pylori isolates. Some 
studies have compared macrolide consumption and 
ensuing resistance in corresponding countries over the 
years. In Japan, clarithromycin consumption increased 
four-fold between 1993 and 2000, and this resulted in 
a fourfold increase in clarithromycin resistance (Perez 
et al., 2002). Therefore, the prevention of unnecessary 
macrolide consumption can contribute to a halting of 
increases in clarithromycin resistance. The detection 
of clarithromycin resistance must, then, constitute the 
first step in any effective strategy for increasing 
resistance.
  Clarithromycin resistance was higher among the 
duodenal ulcer patients (40.9%) than in the functional 
dyspepsia patients (23.1%). The majority of studies 
have mentioned no differences in prevalence in 
accordance with patient disease status, although two 
studies did mention such differences (Broutet et al., 
2003; Megraud, 2003). Strains from 5.6% of peptic 
ulcer patients were found to be resistant, as compared 
with 16.7% of strains obtained from the non-ulcer 
dyspepsia patients (p=0.0005) (Broutet et al., 2003).
  After the culturing of H. pylori from biopsy 
samples, we collected all of the colonies from the 
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culture and used them to isolate H. pylori DNA. As 
infection with multiple strains is common (Hirschl et 
al., 1994; van Doorn et al., 1998), tests will appear 
false if only a few colonies of a culture are examined 
(Jorgensen et al., 1996). A total of 22 patients 
(25.3%) who harbored both the iceA1 and iceA2 
genotypes simultaneously were considered to have 
been infected with more than one strain. No 
significant associations were found between functional 
dyspepsia or duodenal ulcer and iceA genotypes 
(iceA1 and iceA2). There are conflicting reports on 
this issue. Whereas some studies have detected a 
relationship between iceA genotypes and gastric 
diseases such as peptic ulcer, gastritis, and gastric 
cancer (Nishiya et al., 2000; Ashour et al., 2001; 
Kidd et al., 2001; Wu et al., 2005), some studies 
have reported no such relationship (Yamaoka et al., 
1999; Figueiredo et al., 2001; Godoy et al., 2003; 
Ribeiro et al., 2003; Han et al., 2004; Perng et al., 
2004). In this study, we observed no significant 
association between iceA genotypes and clarithromycin 
resistance. To the best of our knowledge, there have 
been no reports, except for this study, concerning iceA 
genotyping in Turkey. A few studies examining the 
association between virulence factors and macrolide 
resistance found no such association (Damaso et al., 
1999; Loivukene et al., 2000; Godoy et al., 2003). 
The actual biological function of the IceA protein re-
mains unclear. Preliminary studies show that mutants 
of iceA1 lacking this putative protein are unable to 
colonize the stomach in a monkey model, whereas the 
parental wild-type iceA1 strain induces long-term 
colonization in monkeys (Dubois et al., 1996). IceA is 
a novel candidate virulence factor, and will require 
more extensive studies in order to prove the associa-
tion between gastric diseases and other factors, most 
notably resistance. Before prescribing a particular 
eradication therapy modality in H. pylori-positive pa-
tients, the detection of resistance may need to become 
a component of future regimens, and 23S rRNA 
mutation rates will clearly be important.
  In conclusion, we observed a clarithromycin resist-
ance prevalence of 27.5% in the H. pylori strains of 
Turkish patients with duodenal ulcer or functional 
dyspepsia. No relationship was determined to exist 
between iceA genotypes and gastrointestinal diseases. 
We also found no association between iceA genotypes 
and clarithromycin resistance.
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